November 17, 2009

Doctors gird for patient anxiety over Zetia data

By Kelley Luckstein

The good news for Merck & Co's Zetia cholesterol fighter is that doctors do not seem unduly concerned about its latest setback in a clinical trial. The bad news is they think patient anxiety will cause its sales to drop anyway…


Dr. Stephen Kopecky, professor of medicine and cardiovascular disease at the prestigious Mayo Clinic in Rochester, Minnesota, found data showing more serious adverse heart events with Zetia -- 9 vs 2 -- to be particularly worrisome, despite the small numbers. "It will push us more toward giving Niaspan," said Kopecky in a telephone interview.


Reuters by Bill Berkrot, 11/16/09

Tags: Cardiology, cholesterol, Zetia

Please sign in or register to post a reply.
Contact Us · Privacy Policy